Prognostic factors of locally advanced cervical cancer after concurrent chemoradiotherapy: a retrospective study

局部晚期宫颈癌同步放化疗后的预后因素:一项回顾性研究

阅读:2

Abstract

OBJECTIVE: To investigate the prognostic value of magnetic resonance imaging (MRI) features and clinical features in locally advanced cervical cancer (LACC) patients after concurrent chemoradiotherapy (CCRT). METHODS: A total of 189 patients with LACC who received definitive CCRT between May 2018 and December 2020 and underwent MRI, including diffusion-weighted imaging, before and 1 month after initial therapy were recruited for this study. The tumor size and mean apparent diffusion coefficient (ADC(mean)) were evaluated. A Cox proportional hazards model and univariate and multivariate analyses were used to determine the associations of clinical characteristics and imaging factors with progression-free survival (PFS) and overall survival (OS). RESULTS: The median follow-up time was 58 (range: 11-71) months. The 5-year PFS and OS rates were 73.8% and 85.5%, respectively. Univariate analysis revealed that the serum squamous cell carcinoma (SCC) antigen level, tumor stage, pretreatment tumor size, residual disease (RD) and post-treament ADC(mean) were significant predictors of PFS and OS. Positive pelvic lymph node status and adjuvant chemotherapy use after CCRT were unfavorable predictive factors in terms of PFS and OS, respectively. Multivariate analysis revealed that tumor stage, SCC antigen level, and RD were independent predictors of PFS (hazard ratio [HR] = 3.282, P < 0.001; HR = 2.567, P = 0.002; and HR = 1.621, P < 0.001, respectively) and OS (HR = 2.517, P = 0.043; HR = 1.025, P = 0.015; and HR = 1.712, P = 0.008, respectively). When patients were grouped based on the cutoff values for these markers, RD size ≥ 1.1 cm was found to indicate considerably worse PFS and OS. CONCLUSION: Elevated SCC antigen levels, advanced tumor stage, and RD size ≥ 1.1 cm were linked to worse PFS and OS. Furthermore, the ADC(mean) was not a reliable predictor of survival outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。